Your browser doesn't support javascript.
loading
Drug Candidates for Autoimmune Diseases.
Saurin, Sabrina; Meineck, Myriam; Erkel, Gerhard; Opatz, Till; Weinmann-Menke, Julia; Pautz, Andrea.
Afiliación
  • Saurin S; 1st Department of Medicine, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.
  • Meineck M; Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.
  • Erkel G; 1st Department of Medicine, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.
  • Opatz T; Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.
  • Weinmann-Menke J; Department of Molecular Biotechnology and Systems Biology, Technical University, 67663 Kaiserslautern, Germany.
  • Pautz A; Department of Chemistry, Johannes Gutenberg University, 55099 Mainz, Germany.
Pharmaceuticals (Basel) ; 15(5)2022 Apr 20.
Article en En | MEDLINE | ID: mdl-35631330
ABSTRACT
Most of the immunosuppressive drugs used in the clinic to prevent organ rejection or to treat autoimmune disorders were originally isolated from fungi or bacteria. Therefore, in addition to plants, these are valuable sources for identification of new potent drugs. Many side effects of established drugs limit their usage and make the identification of new immunosuppressants necessary. In this review, we present a comprehensive overview of natural products with potent anti-inflammatory activities that have been tested successfully in different models of chronic inflammatory autoimmune diseases. Some of these candidates already have passed first clinical trials. The anti-inflammatory potency of these natural products was often comparable to those of established drugs, and they could be used at least in addition to standard therapy to reduce their dose to minimize unwanted side effects. A frequent mode of action is the inhibition of classical inflammatory signaling pathways, such as NF-κB, in combination with downregulation of oxidative stress. A drawback for the therapeutic use of those natural products is their moderate bioavailability, which can be optimized by chemical modifications and, in addition, further safety studies are necessary. Altogether, very interesting candidate compounds exist which have the potential to serve as starting points for the development of new immunosuppressive drugs.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Alemania